Receipt of investigational medication within 4 weeks prior to participation in the study

Pregnant or breast-feeding

Severe congestive heart failure

Known severe HIV infection

Presence of severe burns

Patients on high dose immunosuppressants

Patients whose death is considered imminent

Patients whose life expectancy for concurrent illness is less than 6 months

Severe hypoxic encephalopathy or persistent vegetative state

Severe liver disease

Patient, legal representative or patient's primary physician not committed to providing full, aggressive life support

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis